Geoffrey Guy, executive chairman of GW Pharmaceuticals, has sold almost £600,000 of shares in the cannabis-based medicine firm to co-founder Brian Whittle.
The purchase of 750,000 shares from Guy at 79p each cost Whittle, who retired as a director at GW last year, £592,500.
Whittle and Guy set up the company in 1998 and listed it on the London Stock Exchange in June 2001.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Guy also gifted, for nil consideration, a further 782,111 shares to Whittle and members of Whittle's family.
Despite transferring over 1.5m shares, or 1.3% of the business, Guy still owns a 15.2% stake.
GW posted a maiden annual profit last month. It made £4m on revenue up to £16.1m from £5.7m thanks to increased sales and milestone revenue from Almirall and Sativax
Top Director Buys
Value: £129,366
Value: £53,480
Value: £35,340
Value: £24,878
Value: £24,878
Value: £22,825
Value: £19,902
Value: £11,750
Value: £11,600
Value: £10,536
Top Director Sells
Value: £592,500
-
Which investment trusts could benefit from lower interest rates?As vehicles for long-term investments, many investment trusts were hit when interest rates rose in 2022. With interest rates expected to fall by the end of the year, could now be the time to invest in one of these unloved sectors?
-
How to protect your personal and financial data from cyber attacksM&S and the Co-op are the latest retailers to suffer from cyber hacks but consumers also need to be vigilant
